Last reviewed dd mmm yyyy. Last edited dd mmm yyyy
Risankizumab is a humanised IgG1 monoclonal antibody that specifically inhibits interleukin 23 (IL-23) by binding to its p19 subunit.
NICE state (1):
Risankizumab, alone or with methotrexate, is recommended as an option for treating active psoriatic arthritis (PsA) in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them. It is recommended only if they have:
Risankizumab is recommended only if the company provides it according to the commercial arrangement.
Results from the 24-week double-blind portion of the KEEPsAKE 1 trial demonstrate that risankizumab is well tolerated and effective for treating diverse clinical manifestations of PsA in patients who have had an inadequate response or intolerance to DMARD therapy (2)
Results from the 24-week, double-blind portion of this phase 3 clinical trial in patients with active PsA reveal that risankizumab was well tolerated and effective in treating patients who have experienced previous intolerance and/or inadequate response to csDMARDs or prior biological therapies (3)
Reference:
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.